Head-to-head · Cost-Efficiency Index
Claya vs Ivy Rx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Claya
Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate.
Visit ClayaIvy Rx
Cost-first shoppers who want the lowest published entry price on a semaglutide microdose, for shoppers comfortable with unresolved pricing terms.
Visit Ivy RxThe verdict
Claya and Ivy Rx tie on the Cost-Efficiency Index at 69/100, so neither wins outright on the numbers. For most shoppers we'd start with Claya (ranked #97, a hair above #102) — Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate. But Ivy Rx is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Claya.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Claya | Ivy Rx |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 69/100 |
| Semaglutide / mo | $149/mo (all doses, compounded) | $97/mo (microdose tier, promotional rate, compounded) |
| Tirzepatide / mo | $199/mo (starting dose, compounded) | $199/mo (brand Mounjaro, compounded) |
| Semaglutide / yr (modeled) | $1,788 | $1,164 |
| Tirzepatide / yr (modeled) | $2,388 | $2,388 |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #97 | #102 |
Claya
69/100Where the value is
- Semaglutide is explicitly 'same price regardless of dosage' at $149/mo, removing dose-tier guesswork
- LegitScript Certified, BBB Accredited, and HIPAA Compliant badges all displayed together
- '$100 off your first month' promo code (100CLAYA) published openly with no intake required to see it
The tradeoffs
- The advertised $149/$199 rates are qualified elsewhere on the same page as available 'with select multi-month plans' — a shopper reading only the 'a month' headline could reasonably assume pure month-to-month billing when a prepay term may be required
- No state coverage list is published anywhere on the public site
Ivy Rx
69/100Where the value is
- Genuinely low entry price on the semaglutide microdose tier ($77/mo)
- HSA/FSA eligible with itemized receipts for reimbursement
- Legal entity is named (Ivy RX PLLC), which many competitors in this batch do not disclose
The tradeoffs
- The standard semaglutide price is shown as a struck-through discount ('$197 $97') with no label clarifying whether $97 is a standing rate or a temporary promo
- The advertised $199/mo tirzepatide rate requires a 12-month upfront lump-sum payment, not month-to-month billing, and a separate unexplained $1,399 vial price appears on the same page
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.